louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02054754: Assessment of Single Doses of Oral Dexanabinol in Healthy Subjects
Official title: Assessment of Safety, Tolerability and Pharmacokinetics of Single Doses of Oral Dexanabinol in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Safety
Tolerability
Pharmacokinetics
Cancer
Keywords: Dexanabinol
Oral
Safety
Tolerability
Pharmacokinetics
Lead sponsor: e-Therapeutics PLC
Sponsor class: INDUSTRY
First posted: 2014-02-04
Enrollment: 40
Sex: MALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to test the safety and observe the pharmacokinetics (distribution and elimination of the drug) of the compound dexanabinol (ETS2101) in healthy male subjects following a single oral dose.


Eligibility criteria: Inclusion Criteria:

* Healthy males aged 18 to 45 years
* Body mass index 18.0 to 32.0 kg/m2, or if outside the range, considered not clinically significant by the investigator

Exclusion Criteria:

* Participation in a clinical research study within the previous 3 months
* Current smokers and those who have smoked within the last 12 months
* History of any drug or alcohol abuse in the past 2 years

Primary outcomes:
measure: Safety and Tolerability Based on the Number of Participants With Adverse Events and Comparison of Baseline and Post Dose Parameters
timeFrame: Participants will be followed until follow up visit, 6-11 days after dosing
Secondary outcomes:
measure: Area Under the Curve of the Compound Dexanabinol (ETS2101) From Pre-dose up to 48 Hours Post Dose
timeFrame: Pre-dose, 0.5,1,1.5,2,3,4,5,6,8,10,12,16,24,36,48 hours post dose
Other outcomes:
measure: Pharmacodynamic Biomarker Assessment
timeFrame: Pre-dose, 1, 6 and 24 hours post dose
Locations:
city: Nottingham
country: United Kingdom
facility: Quotient Clinical
state: Nottinghamshire
Study officials:
affiliation: Quotient Clinical
name: Philip Evans, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT07010354: A Registry to Evaluate Safety, Performance, and Clinical Benefit of BeFlow
Official title: An International, Multi-centre Registry to Evaluate Safety, Performance, and Clinical Benefit of the BeFlow Iliac Covered Stent System
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Iliac Artery Stenosis
Iliac Artery Occlusion
Lead sponsor: Bentley InnoMed GmbH
Sponsor class: INDUSTRY
Collaborators: name: ID3 Medical
First posted: 2025-06-08
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adult patients (≥ 18 years of age) suffering from stenotic lesions in the iliac arteries caused by arteriosclerosis or other pathologies that may be treated by stenting.

Brief summary: This international, observational multi-centre registry of the device BFI will monitor technical success of the implantation, data regarding clinical performance, clinical benefit, as well as potential unknown side effects pursuant to the Intended Purpose.


Eligibility criteria: Inclusion Criteria:

* Patients with an indication for permanent intraluminal placement in iliac arteries for restoring and improving the patency impaired by arteriosclerosis or other stenoses that may be treated by stenting according to the IFU of the BFI
* Patient is capable and willing to sign an informed consent
* Patients ≥18 years of age at the time of consent

Exclusion Criteria:

* Patients with any contraindication according to the IFU
* Previous stenting of the target vessel

Primary outcomes:
measure: Primary patency rate
timeFrame: 12 months
Secondary outcomes:
measure: Rate of covered stent-related complications
timeFrame: 1 month and 12 months
measure: Rate of technical success
timeFrame: up to 1 month
measure: Primary patency rate
timeFrame: up to 60 months
measure: Secondary patency rate
timeFrame: up to 60 months
measure: Primary assisted patency rate
timeFrame: up to 60 months
measure: Change of Rutherford Classification
timeFrame: up to 60 months
measure: Change of ABI
timeFrame: up to 60 months
measure: Freedom from TLR
timeFrame: up to 60 months
measure: Freedom from MACE
timeFrame: up to 60 months
Other outcomes:
Locations:
city: Dendermonde
country: Belgium
facility: AZ Sint Blasius
city: Lugano
country: Switzerland
facility: EOC - Ente Ospedaliero Cantonale
state: Ticino
Study officials:
References:
Clinical trial NCT03996954: Validation of a Smartphone-based Recorder for Detection of Cardiac Arrhythmias
Official title: Validation of a Smartphone-based Recorder for Detection of Cardiac Arrhythmias
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cardiac Arrhythmia
Lead sponsor: Blackpool Teaching Hospitals NHS Foundation Trust
Sponsor class: OTHER
First posted: 2019-06-25
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Recordings with Alivecor and 12 lead ECGs with be acquired from patients with known arrhythmias/normal heart rhythm and blinded physicians will report on recordings and ECGs. Reports for each patient will be compared at the end of the study in order to assess diagnostic accuracy of the Alivecor to detect and differentiate between different kinds of abnormal heart rhythms.
Primary purpose: DIAGNOSTIC

Brief summary: The investigators will evaluate the diagnostic yield of the new AliveCor device versus a 12 lead ECG when used simultaneously to detect cardiac arrhythmia

Detailed description: The investigators are planning to record 250 pre-defined abnormal ECGs (50 each of atrial fibrillation, atrial flutter, pre-excitation, ventricular tachycardia, , supraventricular tachycardia) and 150 control ECGs (100 sinus rhythm, 50 sinus tachycardia) using both the AliveCor Smartphone device and a 12-lead ECG. All 400 ECGs will then be read by 3 blinded reporters - a Consultant Electrophysiologist, a Consultant General Cardiologist and a General Practitioner. The output of the AliveCor automatic detection algorithm will also be recorded as a fourth reporter. The screening characteristics of all 4 reporters using the AliveCor device vs the definitive 12 lead ECG will be analysed and compared.

Eligibility criteria: Inclusion Criteria:

* Male or female patients \>18 years
* 12 lead ECG finding of arrhythmia, manifest pre-excitation, pacing rhythm (in the EP lab), sinus rhythm or sinus tachycardia

Exclusion Criteria:

* Age \<18 years
* Patients unable to or unwilling to use the device
* Patients with cardiac pacemaker, ICDs, or other implanted electronic devices

Primary outcomes:
measure: Diagnostic accuracy of alivecor recording
timeFrame: Diagnostic accuracy of Alivecor recording at the end of the study which will be 2 years after study start date.
Secondary outcomes:
Other outcomes:
Locations:
city: Blackpool
country: United Kingdom
facility: Blackpool Teaching Hospitals NHS Foundation Trust
state: Lancashire
Study officials:
affiliation: Blackpool Teaching Hospitals NHS Foundation Trust
name: Khalid Abozguia, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03508154: Evaluation of Carbohydrates - Glycemic Index
Official title: Evaluation of Carbohydrates: Glycemic Index of Nutrition Product Formulation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Glycemic Index
Lead sponsor: Abbott Nutrition
Sponsor class: INDUSTRY
First posted: 2018-04-25
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: This study is an open-label with a randomized, cross-over design using standard GI methodology.


Eligibility criteria: Inclusion Criteria:

* Subjects are males or non-pregnant females in good health
* Subjects must be eligible to receive income in Canada and must demonstrate OHIP or equivalent medical coverage.

Exclusion Criteria:

* Subjects with any type of food allergy or known history of AIDS, hepatitis, diabetes or a heart condition
* Subjects taking medication, or with any condition which might, in the opinion of the PI either make participation dangerous to the subject or to others or affect the results

Primary outcomes:
measure: Blood glucose response curve
timeFrame: 0 to 120 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Glycemic Index Laboratories Inc.
state: Ontario
Study officials:
affiliation: Abbott Nutrition
name: Anne Dumas
role: STUDY_CHAIR
References:
Clinical trial NCT05941754: A Clinical Study of Omega-3 on Depression and Cognition
Official title: A Clinical Study of Omega-3 on Depression and Cognition
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Depression
Keywords: omega-3
cognition
depression
Lead sponsor: Nanfang Hospital, Southern Medical University
Sponsor class: OTHER
First posted: 2023-07-12
Enrollment: 64
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Depression is a serious mental illness, with persistent depression and loss of interest as the main clinical manifestations, and causes varying degrees of cognitive impairment, further leading to impaired social function, and even lead to suicidal behavior. Previous studies on the antidepressant effects of Omega-3 mainly focused on chronic effects, and there was a lack of corresponding rapid response clinical studies. Because of the nature of Omega-3 health products, no clinical adverse effects have been reported. We have previously shown that Omega-3 can produce antidepressant and cognitive improvement effects. This study will carry out different doses (low dose and high dose) and single active ingredient (EPA alone) to observe the antidepressant and cognitive improvement effects of Omega-3 in clinical patients with major depression. The antidepressant effect and cognitive improvement effect of Omega-3 will be further verified to provide evidence for future clinical application.


Eligibility criteria: Inclusion Criteria:

* current moderate to severe depressive episode (DSM-5)
* HAMD-17\>16
* 18≤Age≤45
* Never use of fluoxetine and no use of any antipsychotic and antidepressant drugs and mood stablizer at least 8 weeks
* Current physical or laboratory tests show good health
* negative usrine drug tests
* voluntray to sign the consent form

Exclusion Criteria:

* treat-resistant depressive disorder
* other axis I/II dignoses
* MMSE≤27 recent abuse history of alcohol or drugs pregnant or breast breeding

Primary outcomes:
measure: depressive symptom
timeFrame: 40 minutes
Secondary outcomes:
measure: Cognitive performance Working memory
timeFrame: 4 hours
measure: Cognitive performance Verbal memory
timeFrame: 4 hours
measure: Cognitive performance Visual memory
timeFrame: 4 hours
measure: Cognitive performance
timeFrame: 4 hours
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Nanfang Hospital
state: Guangdong
Study officials:
References:
Clinical trial NCT00824954: Extracorporeal Photopheresis in Children and Young Adults With Refractory Acute Graft Versus Host Disease
Official title: Evaluation of Extracorporeal Photochemotherapy in Children and Young Adults With Refractory Acute Graft Versus Host Disease After Allogeneic Stem Cell Transplantation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Graft Versus Host Disease
Keywords: 0 to 30 years
Refractory Acute GVHD
Lead sponsor: University Hospital, Clermont-Ferrand
Sponsor class: OTHER
First posted: 2009-01-19
Enrollment: 30
Sex: ALL
Maximum age (years): 30
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Purpose : to evaluate the efficacy of ECP in children with refractory acute GVHD This study addresses patients with persistent GVHD after steroid and/or monoclonal antibody therapy

Detailed description: One arm. Six sessions in two weeks. Classification in complete response (resolution of all signs of GVHD), partial response (improvement of at least one grade) or absence of response (Glucksberg criteria). Tapering depending on patient condition during weeks 2 to 10. Final evaluation at week 10. Steroid therapy tapering at the discretion of the investigator.

Eligibility criteria: Inclusion Criteria:

* 0 to 30 years
* Acute GVHD refractory to steroids (disease progression after 2 days or absence of response after 4 days) and/or second line therapy (absence of response after 8 days)
* patient consent and/or parent consent

Exclusion Criteria:

* less of 10 kgs BW
* clinical or biological state precluding the apheresis
* previous GVHD therapy with anti-lymphocyte serum (excepted in the conditioning regimen)

Primary outcomes:
measure: GVHD grading
timeFrame: during weeks 2 to 10
Secondary outcomes:
measure: Overall survival Incidence of chronic GVHD
timeFrame: during weeks 2 to 10
Other outcomes:
Locations:
city: Clermont-Ferrand
country: France
facility: CHU Clermont-Ferrand
Study officials:
affiliation: University Hospital, Clermont-Ferrand
name: Etienne Merlin
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05103254: Bempedoic Acid Pregnancy Surveillance Program
Official title: A Post-marketing, Long-term, Observational, Descriptive Study to Assess the Risk of Pregnancy and Maternal Complications and Adverse Effects on the Developing Fetus, Neonate, and Infant Among Women Exposed to Bempedoic Acid or Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) During Pregnancy
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Pregnancy
Hyperlipidemias
Keywords: bempedoic acid
Lead sponsor: Esperion Therapeutics, Inc.
Sponsor class: INDUSTRY
First posted: 2021-11-02
Enrollment: 20
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Primary care

Brief summary: Bempedoic acid pregnancy surveillance program

Detailed description: A surveillance study of females exposed to bempedoic acid or bempedoic acid/ezetimibe fixed combination drug product (FCDP) during pregnancy. Observational outcome data will be collected on pregnant females through pregnancy and infants through the first year of life.

Eligibility criteria: Inclusion Criteria:

Exposure to at least 1 dose of bempedoic acid or bempedoic acid/ezetimibe FCDP at any time during pregnancy (from first day of last menstrual period \[LMP\] to pregnancy outcome

Exclusion Criteria:

Primary outcomes:
measure: Major congenital malformations (MCM)
timeFrame: Birth up to 12 months
Secondary outcomes:
measure: Minor congenital malformation
timeFrame: Birth up to 12 months
measure: Spontaneous abortion
timeFrame: Time of conception up to birth
measure: Stillbirth
timeFrame: Time of conception up to birth
measure: Elective termination
timeFrame: Time of conception up to birth
measure: Preterm birth
timeFrame: Time of conception up to birth
measure: Small for gestational age (SGA)
timeFrame: Birth up to 12 months
measure: Postnatal growth deficiency
timeFrame: Birth up to 12 months
measure: Infant development deficiency
timeFrame: Birth up to 12 months
Other outcomes:
Locations:
city: Morrisville
country: United States
facility: Evidera, PPD business unit
state: North Carolina
Study officials:
affiliation: Esperion Therapuetics
name: Christine Broestl, MS
role: STUDY_DIRECTOR
References:
Clinical trial NCT02469454: Effect of t of the Etonogestrel Releasing Implant on Infant Growth and Development
Official title: Effect of the Immediately Postpartum Insertion of the Etonogestrel Releasing Implant on Infant Growth and Development
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Contraception
Newborn
Child Development
Growth
Keywords: etonogestrel-implant
newborn
growth
Child Development
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
First posted: 2015-06-11
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: This study aims to assess whether there is change in the growth and development of newborns whose mothers will have a etonogestrel (ENG) releasing implant inserted in the first 24 to 48 hours of delivery compared with those with standard implant insertion (6 week postpartum).


Eligibility criteria: Inclusion Criteria:

* Women who desire to use the ENG implant as a contraceptive method and desire to breastfeed her newborn for ate least 3 months;
* With no contraindication to breastfeeding, whose newborn is healthy, without malformations, born at term (gestational age ≥ 37 weeks), with appropriate weight for gestational age and with normal sucking ability

Exclusion Criteria:

* Tobacco smokers, drug addicts or alcoholics;
* Women with educational levels lower than 5 years;
* Women with clinical conditions considered category 3 and 4 for implant use by the WHO;
* Women with histories of psychiatric illness;
* Women using medications that could alter the concentration of ENG,
* Women with known allergies to the local anesthetic lidocaine (used to place the implant);
* Women who wanted to keep their cyclic menstrual bleeding

Primary outcomes:
measure: neonatal growth
timeFrame: 12 months
Secondary outcomes:
measure: child development
timeFrame: 12 months
Other outcomes:
Locations:
city: Ribeirao Preto
country: Brazil
facility: Clinical Hospital of Sao Paulo University
state: SP
Study officials:
affiliation: Sao Paulo University
name: Carolina S Vieira, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Vieira CS, de Nadai MN, de Melo Pereira do Carmo LS, Braga GC, Infante BF, Stifani BM, Ferriani RA, Quintana SM. Timing of postpartum etonogestrel-releasing implant insertion and bleeding patterns, weight change, 12-month continuation and satisfaction rates: a randomized controlled trial. Contraception. 2019 Oct;100(4):258-263. doi: 10.1016/j.contraception.2019.05.007. Epub 2019 May 27.
citation: Carmo LSMP, Braga GC, Ferriani RA, Quintana SM, Vieira CS. Timing of Etonogestrel-Releasing Implants and Growth of Breastfed Infants: A Randomized Controlled Trial. Obstet Gynecol. 2017 Jul;130(1):100-107. doi: 10.1097/AOG.0000000000002092.
Clinical trial NCT05296954: Localization of Anatomical Structures Involved in Nodal Tachycardias by High Density Mapping.
Official title: Localization of Anatomical Structures Involved in Nodal Tachycardias by High Density Mapping. Feasibility Study.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Atrioventricular Nodal Reentry Tachycardia
Supraventricular Tachycardia
Keywords: Voltage mapping
Atrioventricular node mapping
Lead sponsor: University Hospital, Toulouse
Sponsor class: OTHER
First posted: 2022-03-25
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The aim of the present work is to analyze the capacity of high resolution mapping systems to determine the precise location of the AV node and peri-nodal slow-conducting pathways, using standard recording parameters, but also off-line additional filter changes and additional techniques (conduction velocities, isochrones and dV/dt). The investigative team plan a prospective monocentric study.

Detailed high resolution mapping of the Koch triangle and neighboring areas will be collected through the RHYTHMIA HDx 3D electro-anatomical mapping system and the multipolar ORION catheter. This sample will consist of 2 groups of patients: the first will include patients referred for AVNRT ablation and the second will include control patients (without AVNRT), referred for another indication requiring similar mapping system. If visualized, position of the slow pathway and AV node will be compared with the ablation areas, which will be set conventionally under fluoroscopy.


Eligibility criteria: Inclusion Criteria:

Group 1: Patients without heart disease presenting with reciprocal tachycardia by intra-nodal reentry.

Group 2: Control subjects, without nodal tachycardia, without heart disease, and admitted for ablation of atrial fibrillation or ventricular extrasystoles on a healthy heart and with a 3D system.

Exclusion Criteria:

* Presence of underlying structural heart disease or history of atrial ablation or atrial tachycardia
* Minor or protected patient
* Patient under guardianship, curatorship or safeguard of justice

Primary outcomes:
measure: Determine the precise location of the AV node
timeFrame: 7 months
Secondary outcomes:
Other outcomes:
Locations:
city: Toulouse
country: France
facility: CHU de Toulouse
Study officials:
affiliation: University Hospital, Toulouse
name: Philippe MAURY, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01286454: This Is A Study Of Bioavailability And Food Effect For Fesoterodine.
Official title: An Open-Label, Single-Dose, Randomized, Cross-Over Study To Estimate The Bioavailability And Food Effect Of 4 Mg Fesoterodine Extended Release Beads-In-Capsule Formulations Compared To Commercial Tablet Formulation In Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Overactive Bladder (OAB) With Symptoms of Frequency, Urgency, and Urgency
Keywords: BIOAVAILABILITY
FOOD EFFECT
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2011-01-31
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: This Is A Study Of Bioavailability And Food Effect For Fesoterodine.

Detailed description: To estimate the bioavailability of three different 4 mg fesoterodine ER beads-incapsule formulations compared to 4 mg fesoterodine marketed ER tablets under fasting and fed conditions.

Eligibility criteria: Inclusion Criteria:

* Healthy male and/or female subjects between the ages of 18 and 55 years

Exclusion Criteria:

* Evidence or history of clinically significant disease

Primary outcomes:
measure: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] for Fesoterodine Metabolite (5-hydroxymethyltolterodine [5-HMT])
timeFrame: 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36 and 48 hours (hrs) post dose
measure: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Fesoterodine Metabolite (5-HMT)
timeFrame: 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36 and 48 hrs post dose
measure: Maximum Observed Plasma Concentration (Cmax) for Fesoterodine Metabolite (5-HMT)
timeFrame: 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36 and 48 hrs post dose
Secondary outcomes:
measure: Time to Reach Maximum Observed Plasma Concentration (Tmax) for Fesoterodine Metabolite (5-HMT)
timeFrame: 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36 and 48 hrs post dose
measure: Plasma Decay Half Life (t1/2) for Fesoterodine Metabolite (5-HMT)
timeFrame: 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36 and 48 hrs post dose
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Pfizer Investigational Site
state: Connecticut
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References: